In a marketplace increasingly populated by environmentally conscious consumers, companies have been adapting by offering “greener” products. Unfortunately, many companies are misrepresenting or exaggerating the eco-friendly nature of their wares, a form of false advertising that has become known as “greenwashing.”
Continue reading " “Greenwashing”: The New False Advertising " »
The NYTIMES reported over the weekend, that a Veteran’s Affair Medical Center, located in Philadelphia, PA, had a “rogue cancer unit … that operated with virtually no outside scrutiny and botched 92 of 116 cancer treatments over a span of more than six years — and then kept quiet about it.”
The U.S. Attorneys Office in Philadelphia has filed charges against various executives of Synthes, Inc., a subsidiary of Norian Corp., for “illegally tested bone cement during spinal surgery on about 200 patients, three of whom died on the operating table.”
A new study from the May 27 issue of the Journal of the American Medical Association (JAMA) entitled "Acid-Suppressive Medication Use and the Risk for Hospital-Acquired Pneumonia" has found that hospital patients who are given certain heartburn drugs like Prilosec, Nexium, and Prevacid are at higher risk for pneumonia than those who are not given these medications. In fact, the study determined that there was a 30% increased risk for pneumonia among hospital patients taking these types of medications, called proton-pump inhibitors (PPIs).
Continue reading " Heartburn Drugs Linked to Pneumonia in Hospital Patients " »
In a recent federal lawsuit filed by the City of Baltimore, there are new allegations that the financial institution Wells Fargo, “systematically singled out blacks in Baltimore and suburban Maryland for high-interest subprime mortgages.”
This week, the Food and Drug Administration (FDA) notified doctors and other healthcare professionals about the risk of serious liver injuries, including liver failure and death, related to use of the antithyroid drug Propylthiouracil. Propylthiouracil is considered a second-line drug to Methimazole in the treatment of hyperthyroidism and Graves' Disease. Methimazole only had five reports of serious liver injuries associated with it compared to the thirty-two (32) reported cases associated with Propylthiouracil. Thirteen of those thirty-two cases resulted in death.
Continue reading " FDA Warns of Hepatoxicity with Propylthiouracil " »
